Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Clark Nardinelli"'
Autor:
Rosemarie L. Summers, Dallas W. Wood, Nellie Lew, Shawn A. Karns, Mary K. Muth, Clark Nardinelli, Janet G. Peckham, Carolyn Wolff
Publikováno v:
Journal of Benefit-Cost Analysis. 13:34-56
Partial equilibrium models have been used extensively by policy makers to prospectively determine the consequences of government programs that affect consumer incomes or the prices consumers pay. However, these models have not previously been used to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::426298e337b3eb876b81cdf74331f7e6
https://doi.org/10.1017/bca.2022.1
https://doi.org/10.1017/bca.2022.1
Autor:
Clark Nardinelli, Elizabeth R. Botkins, Aaron Kearsley, Nellie Lew, Carolyn Wolff, Bern Caudill Dealy
Publikováno v:
Applied Economics. 53:1112-1126
Pharmacists dispense prescription drugs with leaflets containing information about the specific medication a patient receives. These leaflets vary in format, length, content, and readability for th...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29d109a0e242ed6b57a3c4c31cc456dc
https://doi.org/10.1080/00036846.2020.1826401
https://doi.org/10.1080/00036846.2020.1826401
Publikováno v:
The Quarterly Review of Economics and Finance. 67:219-226
The US Food and Drug Administration offers multiple designations for drugs under development, such as the fast-track designation (for drugs that treat serious conditions with unmet medical need) and the orphan drug designation (for drugs that treat r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b78ee4555affd37438039ff0fbb54b88
https://doi.org/10.1016/j.qref.2017.07.005
https://doi.org/10.1016/j.qref.2017.07.005
Publikováno v:
Journal of Benefit-Cost Analysis. 9:496-518
Food and Drug Administration (FDA) published a final regulation in 2004 that requires pharmaceutical manufacturers to place linear bar codes on certain human drug and biological products. The intent was that bar codes would be part of a system where
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d669011183f48bdc8ac26007d28c7ec
https://doi.org/10.1017/bca.2018.11
https://doi.org/10.1017/bca.2018.11
Autor:
Clark Nardinelli
Publikováno v:
Journal of Benefit-Cost Analysis. 9:519-530
Practitioners of benefit-cost analysis face many difficulties. Despite the best training, guidance, and intentions, practitioners can stumble: actual benefit-cost analysis is hard and mistakes get made. Over the years, I have collected the mistakes I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e458af3548961f3233cfd84d661e581e
https://doi.org/10.1017/bca.2018.18
https://doi.org/10.1017/bca.2018.18
Publikováno v:
Managerial and Decision Economics. 38:581-594
Pharmaceutical firms are reluctant to disclose proprietary information about a drug's likelihood of approval by the U.S. Food and Drug Administration (FDA) for fear of losing their competitive advantage. Instead, firms may use signals, like the FDA f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63fc380e3f70c11db4ce30f9197c493f
https://doi.org/10.1002/mde.2805
https://doi.org/10.1002/mde.2805
Publikováno v:
Risk Analysis. 35:1125-1139
We present an economic welfare-based method to estimate the health costs associated with foodborne illness caused by known viruses, bacteria, parasites, allergens, two marine biotoxins, and unspecified agents. The method generates health costs measur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08f8033138e8623d4a0e5ae3dcae8764
https://doi.org/10.1111/risa.12316
https://doi.org/10.1111/risa.12316
Publikováno v:
Drug Saf
INTRODUCTION: An important goal in drug regulation is understanding serious safety issues with new drugs as soon as possible. Achieving this goal requires us to understand whether information provided during the Food and Drug Administration (FDA) dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e016fff6ca991d3302df89ee272dee0
https://pubmed.ncbi.nlm.nih.gov/28342075
https://pubmed.ncbi.nlm.nih.gov/28342075
Publikováno v:
Health Economics. 24:617-624
For products such as tobacco and junk food, where policy interventions are often designed to decrease consumption, affected consumers gain utility from improvements in lifetime health and longevity but also lose utility associated with the activity o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d1c745f4e6b9d0017cc4c508336e270
https://doi.org/10.1002/hec.3040
https://doi.org/10.1002/hec.3040
Publikováno v:
Medical Care. 50:987-992
The Food and Drug Administration (FDA) issued a Public Health Advisory entitled "Suicidal Thinking in Children and Adolescents Being Treated with Strattera (Atomoxetine)" on September 29, 2005. At FDA's request, the manufacturer subsequently added a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fe954592dfdf116e26e0b376b9b6ff6
https://doi.org/10.1097/mlr.0b013e31826c86f1
https://doi.org/10.1097/mlr.0b013e31826c86f1